| Management target | Revenue 20.0% |
|---|
| Revenue growth | Q2 +17.3% YoY; H1 +12% |
|---|---|
| Margins | Q2 EBITDA 21.6%; target 25%+ in two years |
| Demand visibility | 96% utilisation; management cites strong demand visibility |
Growth
Q2 revenue +17.3% YoY; H1 revenue +12%. H1 PAT ₹8.17 Cr vs ₹5 Cr (+73%).
Outlook
Two-year aim: revenue CAGR 20%+, EBITDA margin 25%+. Line 3 ~₹60 Cr FY27 revenue; SVP capacity expansion by Q1 FY28.
Risks
Current borrowings doubled to ₹147 Cr; cash fell from ₹81 Cr to ₹2 Cr. Headline PAT growth (26%) conflicts with table (303%).
Last quarter's promises, checked
Delivered
- Guided Q2 SteriPort 'needle may not move much' (Q1 +5% YoY) → Q2 +17.3% YoY (= BEAT)
Partly delivered
- Guided Line 3 commissioning end-Aug 2026 → commissioned Sept 2026 (= PARTIAL)
- Guided ~22% EBITDA margin held → Q2 21.6% (= PARTIAL)
Missed
- Guided SVP facility by Q4 FY27 (Mar-27) → now Q1 FY28 (= MISS)
- Guided Line 3 ~₹70 Cr 7-month revenue → ~₹60 Cr FY27 (= MISS)
- Guided ₹30-35 Cr annual debt reduction → borrowings doubled to ₹147 Cr (= MISS)
Investor Presentation filed with BSE, NSE: AMANTA. Summary written with AI assistance from the document.
Amanta Healthcare Ltd: key numbers
- Share price
- ₹185.45
- Market cap
- ₹720.1 Cr
- Revenue (annual)
- ₹287.7 Cr
- Net profit (annual)
- ₹14.88 Cr
- P/E (TTM)
- 39.3×Sector 41.3×
- Promoter holding
- 63.80%+0.00% QoQ
- FII holding
- 0.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amanta Healthcare Ltd
All →Amanta Healthcare Results Update
Amanta Healthcare reported Q2FY27 revenue of ₹83.13 crore and PAT of ₹4.86 crore, both up sharply YoY. SteriPort Line 3 was commissioned, raising bottle capacity to 11.6 crore.
- SteriPort bottle capacity
- 11.6 crore bottles
Amanta Healthcare Q2 FY27 Results: Net Profit ₹4.9 Cr, Up 308.3% YoY
Amanta Healthcare Ltd reported revenue from operations of ₹83.1 Cr (+17.2% YoY) and net profit of ₹4.9 Cr (+308.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹4.9 Cr · +308.3% YoY
Amanta Healthcare Other Announcement
Amanta Healthcare's quarterly shareholding pattern as at 30 Sep 2026 shows promoter and promoter group holding at 31.33%. The filing notes a gift-based promoter group addition, but is a routine periodic disclosure.
Amanta Healthcare Management Change
Amanta Healthcare's COO Shri Anil Rathi resigned effective October 29, 2026. The departure is disclosed under Regulation 30 of the SEBI Listing Regulations.
Amanta Healthcare Board Meeting Date
Amanta Healthcare intimated a Board Meeting scheduled for 3 Nov 2026 to approve Q1 & H1 FY27 unaudited results. Trading window reopens on 6 Nov 2026.
Amanta Healthcare Other Announcement
Amanta Healthcare Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.